INSTITUTE-FOR-BIOTECH
17.9.2018 15:05:09 CEST | Business Wire | Press release
Taiwan, with high quality medical service and world’s top IT industry, has becoming one of the leaders in global healthcare technology and provider. On November 29 - 30, MEDTEX will focus on 3 key trends: Intelligent Healthcare, Next-generation Biotherapeutics, and Bio-Innovation. Jointed by over 30 world-renowned experts.
At CEO forum , leaders from Merck, Teva, Hitachi, and Nvidia will set the tune of MEDTEX by pushing the boundaries of healthcare through cross-industry collaborations and addressing the upcoming opportunities and challenges.
Follows by Digital Healthcare forum , MEDTEX welcomes Microsoft, Google, Mayo Clinic, and Extensia to discuss topics on how healthcare can leverage AI, AIoT, cloud, and supercomputing to provide a better solution for healthcare management. By incorporating the blockchain decentralization technology, we will see the next level patient-care.
The Immuno-Oncology & Next-generation Biotherapeutics forum focuses on the latest breakthrough in treatments. Starting with cell therapy, immunotherapy to unique topics including gene editing, the spotlight will include Takeda Pharmaceutical, Senior VP to deliberate topics in drug discovery using patient-Derived iPSCs; in the most current stem cell research, we have invite inspiring speakers Eva Feldman from United States to reveal one of the latest stem cell applications; transplantation in ALS. For precision medicine, IBM Watson Health, Harvard Medical University, and Canada’s Genome BC will share trends from evidence-based treatment option, clinical disease-gene discovery and liquid biopsies in cancer.
In Bioinnovation Stadium , J&J innovation center and Novartis will discuss on how to build healthcare innovation cluster and startup strategy, and how do they evaluate those candidates. Biotech organizations from Israel, Australia, Singapore, and UK will address each unique biotechnology ecosystem’s prospectus while bringing more than 15 innovative healthcare companies to showcase their latest technology.
With 400+ major medical centers, technology, pharmaceutical, medical devices organizations participating, MEDTEX and Healthcare+ Expo are for medical professionals, IT, device, pharmaceutical, and biotech companies who wants to find new opportunities and partnering with global healthcare industry players in Asia.
Come and join us, Register Now !
View source version on businesswire.com: https://www.businesswire.com/news/home/20180917005002/en/
Contact:
Taiwan Healthcare+ Expo Gordon Shen, PhD, +886-2-2655-7888 chinhuishen@ibmi.org.tw or David Yang, PhD, +886-2-2655-8168 fmyang@rbmp.org.tw
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 09:00:00 CET | Press release
Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula
1NCE and Netmore Combine Cellular and LoRaWAN Access to Deliver Global IoT Coverage11.3.2026 08:40:00 CET | Press release
The two largest global providers of massive IoT networks partner to provide a combined offering of LoRaWAN® and Cellular connectivity. 1NCE now integrates Netmore’s LoRaWAN into the 1NCE OS platform, allowing customers to use both services seamlessly through its software stack. The new network addresses 90% of the LPWAN market and offers an unparalleled ability to eliminate coverage blind spots around the globe. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform. The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two
1NCE and Netmore Combine Cellular and LoRaWAN Access to Deliver Global IoT Coverage11.3.2026 08:40:00 CET | Press release
The two largest global providers of massive IoT networks partner to provide a combined offering of LoRaWAN® and Cellular connectivity. 1NCE now integrates Netmore’s LoRaWAN into the 1NCE OS platform, allowing customers to use both services seamlessly through its software stack. The new network addresses 90% of the LPWAN market and offers an unparalleled ability to eliminate coverage blind spots around the globe 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform. The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two b
Codethink Opens Early Access to IEC 61508 Mapping for the Eclipse Trustable Software Framework11.3.2026 08:07:00 CET | Press release
Preview release invites industry collaboration on open source approach to functional safety assessment EMBEDDED WORLD--Codethink today opened early access to its mapping between the Eclipse Trustable Software Framework (TSF) and IEC 61508, the international standard governing the functional safety of electrical and electronic systems. The mapping establishes a transparent relationship between the engineering principles of the Trustable Software Framework and the objectives defined in IEC 61508. By making this work available as an early preview, Codethink is inviting organisations interested in applying open source approaches to functional safety to review and begin working with the mapping while the work continues to mature. IEC 61508 forms the foundation of many domain-specific safety standards, including ISO 26262 for automotive systems. The early access reflects Codethink’s long-standing commitment to open development of software engineering methods. “This preview release reflects o
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for futur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom